Dit artikel wordt u aangeboden door Goldman Sachs Asset Management.

Goldman Sachs: A CRISPR Breakthrough

Goldman Sachs: A CRISPR Breakthrough

Gene editing is one example of accelerating innovation in healthcare and as the technology continues to advance, we believe the opportunity to potentially positively impact portfolios may as well.

Read more.

To discuss further, please contact Martijn Hoogendijk (martijn.hoogendijk@gs.com; +31 (0)20 504 25540) or Anja Bogaert (+44 (0)20 7774 7219; anja.bogaert@gs.com).

For full information and important disclosures please follow the links provided. Views and opinions expressed are for informational purposes only and do not constitute a recommendation by GSAM to buy, sell, or hold any security. Confidentiality: No part of this material may, without GSAM’s prior written consent, be (i) copied, photocopied or duplicated in any form, by any means, or (ii) distributed to any person that is not an employee, officer, director, or authorized agent of the recipient. ©2021 Goldman Sachs. All rights reserved.